Clinical Trials Browser

Phase 3 × Bile Duct Neoplasms × Gemcitabine × Clear all

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04003636 2025-04-23

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2025-04-17

MK-3475-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT00658593 2023-08-04

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Phase 3 Terminated

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

NCT02082522 2019-08-28

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Phase 3 Terminated

28 enrolled 24 charts

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT01313377 2017-01-25

Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery

Phase 3 Completed

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

NCT00262769 2012-07-17

ABC-02

Phase 3 Completed

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms